Ⓛ Gene Editing - McAlinden Research Partners

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Gene Editing Markets

FDA Could Approve First CRISPR Treatment in US Before Year End, Marking New Territory for Gene Editing Tech

CRISPR gene editing therapies took a big step toward commercialization in the United States last week, as the FDA laid…

McAlinden Research PartnersJune 13, 2023

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Gene Editing Markets

More FDA Approvals Arise in Gene Editing Space, Renewed VC Rounds Begin to Ramp Up

Shares of biotech firms focused on gene editing have been heating up this month, largely on the back of the…

McAlinden Research PartnersMay 25, 2023

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Gene Editing

FDA Approvals for Genetic Medicines Speed Ahead Despite Recent Setbacks in Base Editing

Shares of biotechnology firms focused on gene editing were slammed this week by an FDA hold placed on Verve Therapeutics'…

McAlinden Research PartnersDecember 8, 2022

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Gene Editing Ⓛ Pharmaceuticals Markets

Pharma Fires Up More M&A Deals in Genetic Medicine as First CRISPR Drug Moves Closer to Commercialization

Mergers and Acquisitions in the biopharma space continue to heat up, fueling a significant increase in large deals through the first 9…

McAlinden Research PartnersOctober 19, 2022

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Gene Editing Markets

CRISPR Tech Closes in on First FDA Approval, New Treatment Methods Continue to Emerge

The US's first marketed CRISPR drug may be set to make its debut in a year or less, following CRISPR…

McAlinden Research PartnersSeptember 29, 2022

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Gene Editing Markets

CRISPR Closing in on First US Product Launch, Latest Data Shows Treatment 100% Effective After Three Years

A decade after its discovery, an authorization of CRISPR drugs to be marketed in the US may only be a…

McAlinden Research PartnersJuly 11, 2022

Copyright © 2019 Catalpa Capital Advisors, LLC. All rights reserved.